While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy. Many of the biggest public companies, especially the technology giants, trade in the hundreds, all the way up to over $1,000 per share or more. At those steep prices, it is difficult to get any decent share count leverage.

Many investors, especially more aggressive traders, look at lower-priced stocks as a way to not only make some good money but to get a higher share count. That can really help the decision-making process, especially when you are on to a winner, as you can always sell half and keep half.

Oppenheimer is one of the top investment banks on Wall Street, so we screened the firm’s outstanding research database and found five biotech stocks trading for less than $10 per share that could provide investors with some solid upside potential.

While all five are rated Overweight at the firm, they are much better suited for aggressive investors. It is important to remember that no single analyst report should be used as a sole basis for any buying or selling decision.

CASI Pharmaceuticals

This micro-cap stock has some big upside to the Oppenheimer price target. CASI Pharmaceuticals Inc. (NASDAQ: CASI) is a biopharmaceutical company that develops and commercializes therapeutics and pharmaceutical products in China, the United States and elsewhere.

The company offers Evomela, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma, which has completed Phase 1 studies in China.

It also provides the following:

• CNCT19 is an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma (NHL).
• BI-1206 is in Phase 1/2 trial in combination with anti-PD1 therapy Keytruda for solid tumors and in a Phase 1/2a trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL.
• CB-5339 is in Phase 1 clinical trial for acute myeloid leukemia and myelodysplastic syndrome, as well as solid tumors and lymphomas.
• CID-103 is for treatment of patients with multiple myeloma.
• Thiotepa has multiple indications, including use as a conditioning treatment for various allogeneic hematopoietic stem cell transplants.
• Octreotide long-acting injectable formulations are for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors.
• Zevaline is used to treat patients with NHL.
• Marqbio is for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.

The Oppenheimer price target for the shares is a whopping $5, while the consensus target is $4.20. The stock recently rose above $1.50 per share.

This is one for traders seeking a health care play. Infinity Pharmaceuticals Inc. (NASDAQ: INFI) is a biopharmaceutical company that focuses on developing novel medicines for people with cancer.

It offers IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma. Its product candidate IPI-549 is an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.

The company has strategic alliances with the following:

• Intellikine, to discover, develop and commercialize pharmaceutical products targeting the delta or gamma isoforms of PI3K
• Verastem, to research, develop, commercialize and manufacture duvelisib and products containing duvelisib, as well as duvelisib program for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma
• PellePharm, to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate

It also has collaboration agreements with Arcus Biosciences, F. Hoffmann-La Roche and Bristol Myers Squibb.

Oppenheimer has a $9 price target, and the consensus target is $8.50. Infinity Pharmaceuticals stock nicely in mid-May and was trading just over $3 on Friday.

Isoray

While perhaps more of a medical products company, its stock could double. Isoray Inc. (NYSE: ISR), through its subsidiary, Isoray Medical, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally.

The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed.

Oppenheimer’s $1.90 price target is lower than the $2.17 consensus target. The stock has traded near $0.80 recently.

This stock has had a very solid run and looks poised to move even higher. PDS Biotechnology Corp. (NASDAQ: PDSB) is a clinical-stage biopharmaceutical company focused on developing multifunctional cancer immunotherapies.

Its lead product candidate is PDS0101 (HPV16), which is in Phase 2 clinical trial and provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies and cervical cancer.

The company is also developing various product candidates, which are in preclinical trials:

• PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers
• PDS0103 (MUC-1) for ovarian, colorectal, lung and breast cancers
• PDS0104, which includes Tyrosinase-related protein 2 for the treatment of melanoma

In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19.

The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova, U.S. Department of Health and Human Services and MSD International.

Oppenheimer has set a $12 price objective. The lower $8.52 consensus target compares to the 52-week high of $7.80 seen late in the week.

Savara

This is another micro-cap idea on which investors can get some sizable share leverage. Savara Inc. (NASDAQ: SVRA) operates as an orphan lung disease company. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.

Earlier this year the company completed a successful secondary offering that raised $130 million. Savara intends to use the net proceeds from the offering for working capital to support operations, including but not limited to clinical development, manufacturing, regulatory and commercial activities related to its molgramostim nebulizer solution (molgramostim, formerly referred to as Molgradex) in autoimmune pulmonary alveolar proteinosis program and the Impala 2 trial, as well as general and administrative expenses.

The Oppenheimer price target is $4. The posted consensus target is $3.80. The stock recently broke through the 200-day moving average and was trading near $1.65.

Get Our Free Investment Newsletter

I have read, and agree to the Terms of Use

These are five stocks for aggressive investors looking to get share count leverage on biotech companies that have sizable upside potential. While not suited for all investors, these are not penny stocks with absolutely no track record or liquidity. Oppenheimer and other Wall Street firms have research coverage.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.